Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

NCT03112681 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cirrhosis

Interventions

DRUG: Saroglitazar magnesium 2 mg
DRUG: Saroglitazar magnesium 4 mg
DRUG: Placebo Oral Tablet

Sponsor

Zydus Therapeutics Inc.